



Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease



Velma T. E. Aho¹ ✉, Matthias Klee², Zied Landoulsi¹, Anna Heintz-Buschart³, Lukas Pavelka^{1,4,5}, Anja K. Leist^{2,20}, Rejko Krüger^{1,4,5,6,20}, Patrick May^{1,20}, Paul Wilmes^{1,7,20} & on behalf of the NCER-PD Consortium*

Gut microbiome differences between people with Parkinson's disease (PD) and control subjects without Parkinsonism are widely reported, but potential alterations related to PD with mild cognitive impairment (MCI) have yet to be comprehensively explored. We compared gut microbial features of PD with MCI ($n = 58$) to cognitively unimpaired PD ($n = 60$) and control subjects ($n = 90$) with normal cognition. Our results did not support a specific microbiome signature related to MCI in PD.

Mild cognitive impairment (MCI) is a non-motor symptom of Parkinson's disease (PD) that represents a risk factor for developing dementia, and can significantly impact quality of life.¹ While gut microbial community differences between people with PD and individuals without parkinsonism are well established^{2–7}, only a single publication has investigated the gut microbiome in PD with MCI, suggesting significant differences in several taxa when contrasting PD with MCI to PD with unimpaired cognition or to control subjects.⁸ To investigate whether these results could be replicated in a larger, geographically distinct cohort, we performed similar comparisons using data from the Luxembourg Parkinson's Study⁴.

Our dataset comprised 58 people with PD and MCI (PD-MCI), 60 people with PD without cognitive impairment (PD-NC), and 90 cognitively normal control subjects. While there were differences in demographic and clinical variables between the control and PD groups, including that controls were younger and had lower frequency of constipation, the PD-MCI and PD-NC groups had similar profiles (Table 1).

We did not observe any difference between the PD-MCI, PD-NC, and control groups in microbial community richness and evenness (alpha diversity) when tested without confounders (Fig. 1a, b, Supplementary Table 1a). In a linear regression model for the inverse Simpson index, including the three groups and potential confounding variables, both PD groups tended to have lower diversity than controls ($0.1 > p > 0.05$; Supplementary Table 1b). In a within-PD model with confounders, there

was no difference between PD with or without MCI (Supplementary Table 1c).

In comparisons of community composition (beta diversity), there was a difference between the three groups when tested with or without confounding variables ($p < 0.001$ for both) (Fig. 1c, Supplementary Tables 2a, b). Pairwise tests between controls and each of the PD groups also showed a significant group effect, but a within-PD test indicated no difference in relation to MCI status (Supplementary Tables 2c–e). In tests of sample dispersions between the groups, the difference was significant between PD-MCI and controls ($p < 0.05$), close to significant between PD-NC and controls ($0.1 > p > 0.05$) and not significant between PD-MCI and PD-NC (Fig. 1d; Supplementary Tables 2f, g).

We performed differential abundance comparisons with three tools: DESeq2⁹ and ANCOM-BC2¹⁰, commonly used methods with different statistical backgrounds, and DA.lic from the DAtest¹¹ package, selected based on its performance compared to other tests (Supplementary Fig 1a–c, Supplementary Table 3a). Comparing controls to the PD groups resulted in many significant taxonomic clades when comparing either PD-MCI or PD-NC to controls (Fig. 1e, Supplementary Fig 1d, Supplementary Table 3b–d). Taxa which were significant with more than one test included, among others, decreased abundances of the family *Lachnospiraceae*, *Clostridiaceae* and *Butyricoccaceae* in PD, and increases in *Enterobacteriaceae* and the genera *Hungatella* and DTU089 (family *Ruminococcaceae*). DESeq2

¹Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg. ²Institute for Research on Socio-Economic Inequality (IRSEI), Department of Social Sciences, University of Luxembourg, Esch-sur-Alzette, Luxembourg. ³Swammerdam Institute of Life Sciences at University of Amsterdam, Amsterdam, the Netherlands. ⁴Parkinson's Research Clinic, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg. ⁵Transversal Translational Medicine, Luxembourg Institute of Health, Strassen, Luxembourg. ⁶Department of Neurology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg. ⁷Department of Life Sciences and Medicine, Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg. ²⁰These authors contributed equally: Anja K. Leist, Rejko Krüger, Patrick May, Paul Wilmes. *A list of authors and their affiliations appears at the end of the paper. ✉e-mail: velma.tea.essi.aho@nmbu.no

Table 1 | Demographic and clinical characteristics of study subjects

Characteristic ^a	Control, N = 90 ^b	PD-NC, N = 60 ^b	PD-MCI, N = 58 ^b	p-value ^c	Control vs. PD-MCI ^d	Control vs. PD-NC ^d	PD-NC vs. PD-MCI ^d
Female sex	39 (43%)	20 (33%)	19 (33%)	0.315			
Constipation	6 (6.7%)	25 (42%)	28 (48%)	<0.001			
Age (years)	68.9 (66.1, 72.5)	71.3 (69.2, 74.9)	73.1 (68.8, 77.9)	0.002	0.001	0.078	0.162
MoCA	28 (27, 29)	28 (27, 29)	23 (22, 25)	<0.001	<0.001	0.777	<0.001
Body mass index	26.8 (24.1, 29.3)	27.6 (24.1, 30.3)	27.7 (25.3, 31.3)	0.055	0.060	0.276	0.427
Years of education	14 (11, 17)	14 (12, 17)	12 (10, 15)	0.061	0.092	0.714	0.092
Caffeine use	84 (93%)	53 (88%)	55 (95%)	0.449			
Spouse in current data	7 (7.8%)	4 (6.7%)	1 (1.7%)	0.309			
Probiotics in last 6 months	3 (3.3%)	2 (3.3%)	1 (1.7%)	>0.999			
Antibiotics in last 6 months	11 (12%)	9 (15%)	3 (5.2%)	0.211			
Vegan or vegetarian diet	2 (2.2%)	3 (5.0%)	2 (3.4%)	0.638			
Years since PD diagnosis		5 (3, 9)	4 (2, 8)	0.400			
Levodopa equivalent daily dosage (mg/day)		475 (339, 806)	472 (300, 874)	0.988			
MDS-UPDRS III		34 (21, 42)	32 (26, 43)	0.833			
Hoehn and Yahr stage		2.00 (2.00, 2.50)	2.00 (2.00, 2.50)	0.978			

^aMoCA Montreal Cognitive Assessment score, MDS-UPDRS Movement Disorder Society Unified Parkinson's Disease Rating Scale.

^bCategorical variables: n (%); continuous variables: median (IQR).

^cCategorical variables: Pearson's Chi-squared test or Fisher's exact test; Continuous variables: one-way ANOVA; PD-only continuous variables: Welch two sample t-test.

^dpairwise t-test with Holm multiple comparison correction.

indicated increases in many additional taxa, such as the genera *Escherichia/Shigella* and *Methanobrevibacter*. However, when comparing PD-MCI to PD-NC, two out of three tests detected no significant taxa (Fig. 1e). DESeq2 highlighted 10 significant taxa for this comparison, notably less than in comparisons between other groups (Supplementary Fig 2a). Among the most significant taxa were genus *Streptococcus* (increased in PD-MCI) and an Amplicon Sequence Variant (ASV) classified as *Akkermansia muciniphila* (decreased in PD-MCI) (Supplementary Fig 2b–e).

Many of the taxa detected as differentially abundant between the PD and control groups were in line with previous publications, including the increased abundances of *Enterobacteriaceae*⁷, *Hungatella*^{5,6} and *Methanobrevibacter*⁶, and decreased abundances of *Lachnospiraceae*^{5–7} and *Butyricococcaceae*^{6,7} in PD. The differences in beta diversity between control and PD subjects were also in line with the literature.^{2–4,6,7} As for comparisons related to PD with MCI, the previous publication on the topic reported a significant difference in beta diversity between PD-NC and PD-MCI, higher abundances of two families and four genera in PD-MCI compared to either PD-NC or controls, and decreases in two genera when contrasting PD-MCI and PD-NC.⁸ In our study, there was no difference in beta diversity between PD with and without MCI. When comparing specific taxa, only one of three tests indicated any differences between PD with and without MCI, and none of those taxa overlapped with the previous publication⁸. Considering the lack of overlap, the two studies do not suggest a consistent microbial signature representative of MCI in PD. The most compelling taxon detected in the present study was an *A. muciniphila* ASV, which was almost entirely absent in PD-MCI. *A. muciniphila* is typically increased in PD^{3–7}, and more research regarding the significance of this taxon in PD and its subtypes is warranted.

To conclude, our comparisons reproduced previously detected differences between PD and control subjects but did not lend support to microbial community patterns specific to PD with MCI.

Methods

Subject recruitment, faecal sample collection and processing as well as amplification and sequencing of the 16 S rRNA gene (regions V3–V4) have been described previously⁴. Participants were included in the present study if they matched UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria¹² for typical PD; subjects with atypical or not yet specified

parkinsonism were excluded. Control subjects genetically related to participants with PD were also excluded. The Luxembourg Parkinson's Study¹³ was conducted according to the Declaration of Helsinki, with approval from the National Ethics Board (CNER Ref: 201407/13) and Data Protection Committee (CNPD Ref: 446/2017). All participants signed written informed consent.

MCI was defined according to Movement Disorder Society (MDS) taskforce criteria¹⁴, using a validated scale for cognitive assessment in PD (Montreal Cognitive Assessment¹⁵; MoCA), and information about the impact of cognitive impairment on daily living. For MoCA, the cutoffs used were <26 and >20. The impact of cognitive impairment was evaluated by MDS-UPDRS (Unified Parkinson's Disease Rating Scale) question 1.1., assessed by a study physician, neuropsychologist, or PD specialized nurse during a semi-structured interview with the participant, together in discussion with family members, where possible. Constipation was defined based on Rome III criteria¹⁶. Levodopa equivalent daily dosage (LEDD) was calculated based on published conversion factors¹⁷.

Sequence data was processed with *dadasnake*¹⁸. Primers were removed using *cutadapt*¹⁹ allowing 20% mismatches and no indels. Quality filtering, ASV (Amplicon Sequence Variant) generation and chimera removal were performed using *DADA2*²⁰. Reads were truncated at positions with Phred score < 10, or at 240 bp. Quality filtering was set to keep sequences with a maximum expected error of 2 and length of 240 bp. Downsampling was performed to 25,000 reads using *seqtk*²¹; samples with fewer reads were removed. ASVs were generated in pooled mode using default parameters. A minimum overlap of 12 bp was required for merging forward and reverse ASVs. Chimeric sequences were removed based on the consensus algorithm. Taxonomic classification was performed against SILVA v. 138²² using the naïve Bayesian classifier implemented in *mothur*²³.

After excluding subjects that did not match diagnostic criteria, control subjects related to PD subjects, and subjects lacking microbiome data, the data contained results from 468 individuals. Additional exclusions were implemented as follows:

1. 236 subjects with age ≤ 64 years due to overrepresentation of younger individuals in the control group,
2. 3 subjects due to missing information on education or body mass index (BMI),




Fig. 1 | Microbial diversity and differential abundance comparisons for Parkinson's disease with and without mild cognitive impairment. **a** Boxplot for richness (Chao1). **b** Boxplot for richness and evenness (inverse Simpson). **c** Community composition visualized as NMDS ordination of Bray-Curtis dissimilarity; ellipses indicate 95% confidence intervals. **d** Boxplot for groupwise distances

to centroid from the ordination, with significances for pairwise comparisons from Tukey HSD test. **e** Numbers of differentially abundant taxa (multiple comparison corrected $p < 0.05$). In boxplots, box hinges represent the 1st and 3rd quartiles, whiskers range from hinge to the highest and lowest values that are within 1.5*IQR of the hinge, and outlines represent data distributions.

- 5 subjects due to having <10,000 sequence reads left after removing rare ASV's (present in <10% of samples) and ASV's classified as chloroplasts or mitochondria,
- 16 subjects due to reported use of corticosteroids or immunosuppressants in the past 6 months.

After these exclusions, the final data set used for analyses consisted of data from 208 individuals.

Statistical comparisons and visualizations were performed in R²⁴ (version 4.3.2), using renv²⁵ (1.0.3) for package management and knitr²⁶ (1.43) for reporting. Comparisons of demographic and clinical variables were performed using Pearson's Chi-squared test or Fisher's exact test

(categorical variables), Welch two sample t-tests (PD-only continuous variables), and one-way ANOVA with post-hoc two-tailed pairwise t-tests and "holm" multiple comparison correction (continuous variables).

Alpha diversity indices were calculated with phyloseq²⁷ (1.42.0) and compared with Wilcoxon rank sum tests (variables with two categories), Kruskal-Wallis tests (variables with more than two categories) or Pearson correlations (continuous variables) as well as linear regression to model multiple variables together. Beta diversity was explored using phyloseq and vegan²⁸ (2.6-4), with data subsampled to the lowest sequence read count in a sample. Bray-Curtis dissimilarity was used as the dissimilarity measure, visualizations were performed with Non-Metric Multidimensional Scaling (NMDS), and statistical comparisons with PERMANOVA (function:

adonis2) using 9999 permutations. Confounder-corrected adonis2 models were run with the option 'by = "margin"' to calculate marginal effects. Additional tests for beta diversity included ANOVA and Tukey-HSD for multivariate homogeneity of group dispersions.

Differential abundance comparisons were performed with DESeq⁹ (1.38.3), ANCOM-BC2 from ANCOMBC¹⁰ (2.1.4), and DA.lic, which implements LIMMA²⁹ with CLR transformed data, from DAtest¹¹ (2.8.0). DA.lic was selected based on the results of testDA from DAtest, which was run 50 times for each method, contrasting PD-NC to PD-MCI with a confounder-corrected model, using PD-only genus and ASV level data (ASVs trimmed to those present in > 30 samples). The final choice was based on test score > 0, false discovery rate < 0.25, and higher power than other similarly performing tests.

The model used for all differential abundance tests was taxon ~ Group (control/PD-NC/PD-MCI)+Sex+Age+BMI+Antibiotic use in past 6 months (yes / no)+Constipation (yes / no) + Education (categorical, split by median). DESeq2 was run with default parameters except for 'sfType = "poscounts"', and results were retrieved for all pairwise comparisons between the three subject groups. DA.lic and ANCOM-BC2 were run twice for each taxonomic level:

1. with full data and all three groups, for which these tests only provide results in relation to the reference level (only PD-NC vs. control and PD-MCI vs. control, not PD-MCI vs. PD-NC),
2. with PD-only data for the PD-MCI vs. PD-NC comparison.

DA.lic was performed using default settings. With ANCOM-BC2, the full data comparison (1) was additionally performed using the pairwise approach, which provides results for all three pairwise comparisons, but is more stringent. Additional parameters included setting 'prv_cut' to 0 and multiple comparison correction to "fdr" for both the default test and the pairwise test.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

Patient data used in the preparation of this manuscript were obtained from the National Centre of Excellence in Research on Parkinson's Disease (NCER-PD). NCER-PD datasets are not publicly available, as they are linked to the Luxembourg Parkinson's Study and its internal regulations. The NCER-PD Consortium is willing to share its available data. Its access policy was devised based on the study ethics documents, including the informed consent form, as approved by the national ethics committee. Requests to access datasets should be directed to the Data and Sample Access Committee via email: request.ncer-pd@uni.lu.

Code availability

The R code for this study is available at <https://gitlab.lcsb.uni.lu/ESB/ncer-mci-microbiome>.

Received: 20 September 2023; Accepted: 15 March 2024;

Published online: 06 April 2024

References

1. Baiano, C., Barone, P., Trojano, L. & Santangelo, G. Prevalence and clinical aspects of mild cognitive impairment in Parkinson's disease: a meta-analysis. *Mov. Disord.* **35**, 45–54 (2020).
2. Scheperjans, F. et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. *Mov. Disord.* **30**, 350–358 (2015).
3. Heintz-Buschart, A. et al. The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder. *Mov. Disord.* **33**, 88–98 (2018).
4. Baldini, F. et al. Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions. *BMC Biol.* **18**, 62 (2020).
5. Nishiwaki, H. et al. Meta-analysis of gut dysbiosis in Parkinson's disease. *Mov. Disord.* **35**, 1626–1635 (2020).
6. Romano, S. et al. Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation. *Npj Park. Dis.* **7**, 27 (2021).
7. Kleine Bardenhorst, S. et al. Gut microbiota dysbiosis in Parkinson disease: A systematic review and pooled analysis. *Eur. J. Neurol.* **30**, 3581–3594 (2023).
8. Ren, T. et al. Gut microbiota altered in mild cognitive impairment compared with normal cognition in sporadic Parkinson's disease. *Front. Neurol.* **11**, 137 (2020).
9. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
10. Lin, H. & Peddada, S. D. Analysis of compositions of microbiomes with bias correction. *Nat. Commun.* **11**, 3514 (2020).
11. Russel, J. et al. DAtest: a framework for choosing differential abundance or expression method. Preprint at <https://www.biorxiv.org/content/10.1101/241802v1> (2018).
12. Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J. Neurol. Neurosurg. Psychiatry* **55**, 181–184 (1992).
13. Hipp, G. et al. The Luxembourg Parkinson's Study: a comprehensive approach for stratification and early diagnosis. *Front. Aging Neurosci.* **10**, 326 (2018).
14. Litvan, I. et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. *Mov. Disord.* **27**, 349–356 (2012).
15. Nasreddine, Z. S. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J. Am. Geriatr. Soc.* **53**, 695–699 (2005).
16. Longstreth, G. F. et al. Functional bowel disorders. *Gastroenterology* **130**, 1480–1491 (2006).
17. Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. *Mov. Disord.* **25**, 2649–2653 (2010).
18. Weißbecker, C., Schnabel, B. & Heintz-Buschart, A. Dadasnake, a Snakemake implementation of DADA2 to process amplicon sequencing data for microbial ecology. *GigaScience* **9**, g1aa135 (2020).
19. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet. J.* **17**, 10–12 (2011).
20. Callahan, B. J. et al. DADA2: High-resolution sample inference from Illumina amplicon data. *Nat. Methods* **13**, 581–583 (2016).
21. Li, Heng. seqtk: a fast and lightweight tool for processing sequences in the FASTA or FASTQ format, <https://github.com/lh3/seqtk> (2023).
22. Quast, C. et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. *Nucleic Acids Res.* **41**, D590–D596 (2013).
23. Schloss, P. D. et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. *Appl. Environ. Microbiol.* **75**, 7537–7541 (2009).
24. R Core Team. R: A Language and Environment for Statistical Computing, <https://www.R-project.org/> (2023).
25. Ushey, K. & Wickham, H. renv: Project Environments, <https://rstudio.github.io/renv/> (2023).
26. Xie, Y. knitr: A General-Purpose Package for Dynamic Report Generation in R, <https://yihui.org/knitr/> (2023).
27. Mcmurdie, P. J. & Holmes, S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. *PLoS ONE* **8**, e61217 (2013).
28. Oksanen, J. et al. vegan: Community Ecology Package, <https://CRAN.R-project.org/package=vegan> (2022).

29. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* **43**, e47 (2015).

Acknowledgements

We would like to thank all participants of the Luxembourg Parkinson's Study for their important support of our research. Furthermore, we acknowledge the joint effort of the National Centre of Excellence in Research on Parkinson's Disease (NCER-PD) Consortium members from the partner institutions Luxembourg Centre for Systems Biomedicine, Luxembourg Institute of Health, Centre Hospitalier de Luxembourg, and Laboratoire National de Santé generally contributing to the Luxembourg Parkinson's Study. Data used in the preparation of this manuscript were obtained from the National Centre of Excellence in Research on Parkinson's Disease (NCER-PD). The National Centre of Excellence in Research on Parkinson's Disease (NCER-PD) is funded by the Luxembourg National Research Fund (FNR/NCER13/BM/11264123). The work was supported by the PEARL program (FNR/P13/6682797 to R.K.), MotaSYN (12719684 to R.K.), MAMaSyn (to R.K.), the FNR/DFG Core INTER (ProtectMove, FNR11250962 to P.M.). P.W. acknowledges funding from the European Research Council under the European Union's Horizon 2020 research and innovation program (no. 863664). A.K.L., R.K., and P.W. acknowledge the financial support of the Institute for Advanced Studies of the University of Luxembourg through an AUDACITY grant (ref. no. MCI-BIOME_2019). The funders played no role in the study design, data collection, analysis and interpretation of data, or the writing of this manuscript. For the purpose of open access, and in fulfillment of the obligations arising from the grant agreement of the Luxembourg National Research Fund, the authors have applied a Creative Commons Attribution 4.0 International (CC BY 4.0) license to any Author Accepted Manuscript version arising from this submission. The sequence data analyses for this study were carried out using the HPC facilities of the University of Luxembourg.

Author contributions

Conceptualization: V.T.E.A., R.K., P.M., P.W.; Data curation: V.T.E.A., Z.L., L.P., and NCER-PD; Formal analysis: V.T.E.A., P.M., A.H.B., M.K.; Writing –original draft: V.T.E.A., Writing –review & editing: all authors; Funding

acquisition: P.M., A.K.L., R.K., P.W.; Project administration: V.T.E.A., P.M., A.K.L., R.K., P.W.; Supervision: P.M., A.K.L., R.K., P.W. All authors read and approved the final manuscript. A.K.L., R.K., P.M., and P.W. share last authorship.

Competing interests

A.K.L. has served on advisory boards and as speaker for Roche. The other authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41531-024-00687-1>.

Correspondence and requests for materials should be addressed to Velma T. E. Aho.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

on behalf of the NCER-PD Consortium

Geeta Acharya⁸, Gloria Aguayo⁸, Myriam Alexandre⁸, Muhammad Ali¹, Wim Ammerlann⁸, Giuseppe Arena¹, Michele Bassis¹, Roxane Batutu⁹, Katy Beaumont⁸, Sibylle Béchet⁹, Guy Berchem⁹, Alexandre Bisdorff¹⁰, Ibrahim Boussaad¹, David Bouvier¹¹, Lorieza Castillo⁸, Gessica Contesotto⁸, Nancy De Bremaeker⁹, Brian Dewitt⁸, Nico Diederich⁹, Rene Dondelinger¹⁰, Nancy E. Ramia¹, Angelo Ferrari⁸, Katrin Frauenknecht¹¹, Joëlle Fritz⁸, Carlos Gamio⁸, Manon Gantenbein⁸, Piotr Gawron¹, Laura Georges⁸, Soumyabrata Ghosh¹, Marijus Giraitis^{8,9}, Enrico Glaab¹, Martine Goergen⁹, Elisa Gómez De Lope¹, Jérôme Graas⁸, Mariella Graziano¹², Valentin Groues¹, Anne Grünewald¹, Gaël Hammot⁸, Anne-Marie Hanff^{8,13,14}, Linda Hansen⁹, Michael Heneka¹, Estelle Henry⁸, Margaux Henry⁸, Sylvia Herbrink⁹, Sascha Herzinger¹, Alexander Hundt⁸, Nadine Jacoby¹⁵, Sonja Jónsdóttir^{8,9}, Jochen Klucken^{1,8,9}, Olga Kofanova⁸, Rejko Krüger^{1,8,9}, Pauline Lambert⁸, Zied Landoulsi¹, Roseline Lentz¹⁶, Laura Longhino⁹, Ana Festas Lopes⁸, Victoria Lorentz⁸, Tainá M. Marques⁸, Guilherme Marques⁸, Patricia Martins Conde¹, Patrick May^{1,20}, Deborah Mcintyre⁸, Chouaib Mediouni⁸, Françoise Meisch¹, Alexia Mendibide⁸, Myriam Menster⁸, Maura Minelli⁸, Michel Mittelbronn^{1,8,11,13,17,18}, Saïda Mtime⁸, Maeva Munsch⁸, Romain Nati⁹, Ulf Nehrass⁸, Sarah Nickels¹, Beatrice Nicolai⁹, Jean-Paul Nicolay¹⁹, Fozia Noor⁸, Clarissa P. C. Gomes¹, Sinthuja Pachchek¹, Claire Pauly^{8,9}, Laure Pauly^{8,13}, Lukas Pavelka^{8,9}, Magali Perquin⁸, Achilleas Pexaras⁸, Armin Rauschenberger¹, Rajesh Rawal¹, Dheeraj Reddy Bobbili¹, Lucie Remark⁸, Ilsé Richard⁸, Olivia Roland⁸, Kirsten Roomp¹, Eduardo Rosales⁸, Stefano Sapienza¹, Venkata Satagopam¹, Sabine Schmitz¹, Reinhard Schneider¹, Jens Schwamborn¹, Raquel Severino⁸, Amir Sharify⁸, Ruxandra Soare¹, Ekaterina Soboleva^{1,9}, Kate Sokolowska⁸, Maud Theresine⁸, Hermann Thien⁸, Elodie Thiry⁹,

Rebecca Ting Jiin Loo¹, Johanna Trouet⁸, Olena Tsurkalenko⁸, Michel Vaillant⁸, Carlos Vega⁸, Liliana Vilas Boas⁹, Paul Wilmes¹, Evi Wollscheid-Lengeling¹ & Gelani Zelimkhanov^{8,9}

⁸Luxembourg Institute of Health, Strassen, Luxembourg. ⁹Centre Hospitalier de Luxembourg, Strassen, Luxembourg. ¹⁰Centre Hospitalier Emile Mayrisch, Esch-sur-Alzette, Luxembourg. ¹¹Laboratoire National de Santé, Dudelange, Luxembourg. ¹²Association of Physiotherapists in Parkinson's Disease Europe, Esch-sur-Alzette, Luxembourg. ¹³Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg. ¹⁴Department of Epidemiology, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre+, Maastricht, the Netherlands. ¹⁵Private practice, Ettelbruck, Luxembourg. ¹⁶Parkinson Luxembourg Association, Leudelange, Luxembourg. ¹⁷Luxembourg Center of Neuropathology, Dudelange, Luxembourg. ¹⁸Department of Life Sciences and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg. ¹⁹Private practice, Luxembourg, Luxembourg.